8-K: Evolent Health Reports Q4 2025 Results Amidst Major Loss

Evolent Health announced its fourth quarter and full year 2025 financial results, reporting a significant net loss driven by goodwill impairment, despite growth in adjusted EBITDA and a strong 2026 revenue outlook.

Summary

• Evolent Health reported a net loss attributable to common shareholders of $(429.1) million for Q4 2025, significantly wider than $(30.6) million in Q4 2024.
• Full year 2025 net loss was $(579.4) million, compared to $(93.5) million in 2024.
• Revenue for Q4 2025 was $468.7 million, a decrease from $646.5 million in Q4 2024.
• Full year 2025 revenue was $1.88 billion, down from $2.55 billion in 2024.
• Adjusted EBITDA for Q4 2025 increased to $37.8 million (8.1% margin) from $22.6 million (3.5% margin) in Q4 2024.
• Full year 2025 Adjusted EBITDA was $151.2 million (8.1% margin), a slight decrease from $160.5 million (6.3% margin) in 2024.
• The company recorded a goodwill impairment of $398.0 million in 2025.
• Cash and cash equivalents increased to $151.9 million as of December 31, 2025, from $104.2 million in 2024.
• Evolent Health forecasts full year 2026 revenue between $2.4 billion and $2.6 billion, representing approximately 30% growth.
• Adjusted EBITDA guidance for full year 2026 is set between $110 million and $140 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to the substantial GAAP net losses and the significant goodwill impairment, which overshadow the positive adjusted EBITDA growth and the optimistic 2026 revenue outlook. The immediate financial performance is concerning, despite management's forward-looking confidence.

Positives

• Adjusted EBITDA for Q4 2025 increased to $37.8 million, up from $22.6 million in Q4 2024, demonstrating improved operational efficiency on an adjusted basis.
• Adjusted EBITDA margin improved significantly to 8.1% in Q4 2025 from 3.5% in Q4 2024, and for the full year 2025 to 8.1% from 6.3% in 2024.
• The company projects robust revenue growth of approximately 30% for full year 2026, with guidance between $2.4 billion and $2.6 billion.
• Strong customer retention and late-stage pipeline activity are reported, indicating continued business momentum.
• Cash and cash equivalents increased to $151.9 million as of December 31, 2025, from $104.2 million in the prior year, improving liquidity.

Negatives

• Evolent Health reported a substantial net loss of $(429.1) million for Q4 2025, a significant deterioration from a net loss of $(30.6) million in Q4 2024.
• The full year 2025 net loss widened dramatically to $(579.4) million from $(93.5) million in 2024.
• A goodwill impairment charge of $398.0 million was recorded in 2025, contributing heavily to the net loss.
• GAAP revenue decreased year-over-year, with Q4 2025 revenue at $468.7 million compared to $646.5 million in Q4 2024, and full year 2025 revenue at $1.88 billion compared to $2.55 billion in 2024.
• Adjusted income attributable to common shareholders decreased for the full year 2025 to $10.4 million from $47.4 million in 2024.
• The company anticipates an impact on Adjusted EBITDA in the first half of 2026 due to new Performance Suite revenue and significant health plan customer membership decreases in their Exchange products.

Risks

• Significant portion of revenue derived from largest partners, with potential for loss, termination, or renegotiation of contracts.
• Increasing number of risk-sharing arrangements with partners, making exposure difficult to predict.
• Growth and success of partners and certain revenues are subject to factors outside of the company's control, including governmental funding reductions and policy changes.
• Inability to accurately predict exposure under performance-based contracts.
• Failure by customers to provide accurate and timely information.
• Ability to recover upfront costs in partner relationships and develop them over time.
• Ability to attract new partners and capture new opportunities.
• Ability to offer new and innovative products and services and keep pace with industry standards, technology, and partner needs.
• Dependency on key personnel and ability to attract, hire, integrate, and retain them.
• Risks related to completed and future acquisitions, investments, alliances, and joint ventures, which could divert management resources, result in unanticipated costs, or dilute stockholders.
• Ability to effectively manage growth and maintain an efficient cost structure, including managing offshore operations and cost reduction goals.
• Competition could limit the ability to maintain or expand market share.
• Risks related to audits by CMS and other governmental payers and actions, including whistleblower claims under the False Claims Act.
• Evolution of the healthcare regulatory and political framework.
• Restrictions on accessing personal data and penalties from privacy and data protection laws.
• Data loss or corruption due to system failures or service disruptions.
• Liabilities and reputational risks related to safeguarding the security and privacy of confidential data.
• Ability to obtain, maintain, and enforce intellectual property rights and protect trademarks and trade names.
• Risks associated with the use of artificial intelligence (AI) and machine learning models, and open-source software.
• Reliance on third parties and licensed technologies, and restrictions on using, disclosing, de-identifying, or licensing data.
• Reliance on Internet infrastructure, bandwidth providers, data center providers, and own systems.
• Ability to achieve profitability in the future.
• Impact of additional goodwill and intangible asset impairments on results of operations.
• Obligations to make material payments to pre-IPO investors for tax benefits, which may be accelerated or exceed realized tax benefits.
• Inability to obtain financing may result in a reduction in stockholder ownership.
• Conditional conversion features and changes in accounting treatment of notes, which may adversely affect financial condition.
• Ability to raise funds necessary to settle conversions of notes in cash, repurchase notes, or pay redemption price.
• Interest rate risk and other restrictive covenants under credit agreements.
• Indebtedness, ability to service it, and ability to obtain additional financing.
• Interference with ability to access credit facilities.
• Potential volatility of Class A common stock price.
• Provisions in certificate of incorporation and by-laws and Delaware law that discourage or prevent strategic transactions.
• Provisions in certificate of incorporation limiting stockholders' ability to obtain a favorable judicial forum.
• Intention not to pay cash dividends on Class A common stock.
• Impact of litigation proceedings, government inquiries, reviews, audits, or investigations.
• Public health emergencies, epidemics, pandemics, or contagious diseases.
• Cost of compliance with sustainability or other environmental, social responsibility, or governance law and regulations.
• Impact of increasing inflationary pressures and rising consumer costs.
• Ability to utilize net operating loss carry forwards and certain other tax attributes may be limited.

Future Outlook

Evolent Health expects full year 2026 revenue to be in the range of approximately $2.4 billion to $2.6 billion, representing about 30% growth. Adjusted EBITDA for 2026 is projected to be between $110 million and $140 million. The company anticipates an impact on Adjusted EBITDA in the first half of 2026 due to new Performance Suite revenue and health plan customer membership decreases, but expects year-end 2026 margins to improve as contract reserving effects ease and operating cost reduction plans ramp up.

Management Comments

• Seth Blackley, Co-Founder and CEO, stated, 'In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model.'
• Blackley also noted, 'We believe our total forecasted revenue growth of approximately 30% for 2026 demonstrates the power and durability of Evolent's specialty model.'
• Blackley acknowledged, 'While the addition of $900 million in new Performance Suite revenue in 2026, as well as the impact of significant health plan customer membership decreases in their Exchange products, create an impact on Adjusted EBITDA in the first half of the year, we believe our year-end 2026 margins should quickly step-up as new contract reserving effects ease throughout the year and our operating cost reduction plan ramps up across 2026.'
• Blackley concluded, 'Most importantly, we believe we will continue to see a sizable market opportunity as health plans turn to Evolent for help in balancing quality and affordability for their members as they navigate oncology, cardiology, and musculoskeletal conditions.'

Industry Context

StockSavvy.ai notes that Evolent Health operates in the highly competitive and evolving healthcare technology sector, specializing in complex specialty care solutions. The company's focus on balancing quality and affordability for conditions like oncology, cardiology, and musculoskeletal aligns with broader industry trends towards value-based care and cost containment for health plans. The reported robust demand for its solutions, despite significant GAAP losses, suggests that its offerings address critical needs within the payer and provider landscape, positioning it to potentially capitalize on the ongoing shift in healthcare delivery models.

Stakeholder Impact

• Shareholders: Will experience significant dilution of earnings per share due to the large net loss and goodwill impairment, potentially impacting stock price volatility. The forward guidance offers a mixed signal, with strong revenue growth but a lower Adjusted EBITDA range than the prior year's actuals.
• Employees: The mention of 'operating cost reduction plan' ramping up across 2026 could imply potential workforce adjustments or efficiency initiatives.
• Customers: Strong customer retention and new Performance Suite revenue additions indicate continued value and engagement, despite some health plan membership decreases impacting the first half of 2026.
• Creditors: The company's increased cash position and positive adjusted EBITDA provide some comfort, but the overall net loss and indebtedness levels remain a factor for credit risk assessment.

Next Steps

• The company expects to deploy approximately $25 million to $35 million in cash for capitalized software development during 2026.
• Management anticipates year-end 2026 margins to step-up as new contract reserving effects ease and operating cost reduction plans ramp up across 2026.

Key Dates

Recommendation

While the significant GAAP net loss and goodwill impairment are major concerns, the company's strong adjusted EBITDA growth in Q4 2025, robust 2026 revenue growth forecast (approx. 30%), and management's expectation for margin improvement in the latter half of 2026 present a mixed picture. The market opportunity for complex specialty care solutions remains strong. A 'hold' recommendation reflects the current financial challenges, particularly the GAAP losses, but acknowledges the underlying operational improvements and future growth potential, suggesting investors monitor the execution of the cost reduction plan and the anticipated margin recovery.

Keywords

Evolent Health, EVH, Healthcare Technology, Specialty Care, Health Outcomes, Financial Results, Earnings, Adjusted EBITDA, Goodwill Impairment, SEC Filing, Form 8-K, Q4 2025, Full Year 2025, 2026 Guidance, Medical Expense Ratio, Performance Suite, Value-Based Care